Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
1(17%)
Results Posted
100%(4 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_1
1
17%
Ph phase_2
3
50%

Phase Distribution

1

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
3(75.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(4)
Terminated(1)

Detailed Status

Completed4
Terminated1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
80.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (25.0%)
Phase 23 (75.0%)

Trials by Status

terminated117%
completed467%
active_not_recruiting117%

Recent Activity

1 active trials
Showing 5 of 6
completed

Immunophenotyping Profiling in Patients With Primary Nephrotic Syndrome

NCT07702981
completedphase_2

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients

NCT03663335
terminatedphase_2

A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation

NCT06365437
completedphase_2

A Dose Escalation Study in de Novo Renal Transplantation

NCT04311632
active_not_recruiting

Impact of Concomitant Use of Steroids and Immune-Checkpoint Inhibitors on Survival Outcomes in NSCLC Patients

NCT06751108
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07702981

Immunophenotyping Profiling in Patients With Primary Nephrotic Syndrome

Completed
NCT03663335Phase 2

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients

Completed
NCT06365437Phase 2

A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation

Terminated
NCT04311632Phase 2

A Dose Escalation Study in de Novo Renal Transplantation

Completed
NCT06751108

Impact of Concomitant Use of Steroids and Immune-Checkpoint Inhibitors on Survival Outcomes in NSCLC Patients

Active Not Recruiting
NCT02217410Phase 1

CCFZ533X2201 - PoC Study in de Novo Renal Transplantation

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6